Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia

Peter C. Trask, David Cella, Nadine Besson, Virginia Kelly, Tamás Masszi, Dong Wook Kim

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Understanding the impact of second-line tyrosine kinase inhibitor therapy on the health-related quality of life (HRQOL) of imatinib (IM)-resistant and IM-intolerant chronic phase chronic myeloid leukemia (CP CML) patients is important given the increased survival that comes with therapy. As part of a bosutinib single-arm phase 2 trial, 200 IM-resistant and 88 IM-intolerant CP CML patients' HRQOL was assessed prior to and throughout treatment with the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu). Little HRQOL impairment was demonstrated at baseline. Over the course of 96. weeks on bosutinib therapy, patients noted statistically significant and/or clinically meaningful improvements on several FACT-Leu scales.

Original languageEnglish
Pages (from-to)438-442
Number of pages5
JournalLeukemia Research
Volume36
Issue number4
DOIs
Publication statusPublished - Apr 1 2012

Keywords

  • Bosutinib
  • Chronic myeloid leukemia
  • Chronic phase
  • FACT-Leu
  • Health-related quality of life

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia'. Together they form a unique fingerprint.

  • Cite this